UMIN-CTR History

Name：　　UMIN ID：

Unique ID issued by UMIN	UMIN000009603
Receipt number	R000011263
Scientific Title	Phase II study evaluating Erlotinib/Bevacizumab therapy as a second line therapy for advanced relapsed EGFR mutation positive non-squamous NSCLC patients who received first line combination therapy including platinum and Bevacizumab
Date of disclosure of the study information	2012/12/21
Last modified on	2012/12/21 12:02:32

---